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Abstract
AIM: This study was conducted to compare means of interleukin-17 (IL-17) (Th17 cytokines) and interleukin-10 
(IL-10) (T-regulatory cytokines) as pro-inflammatory and anti-inflammatory cytokine with disease activity of systemic 
lupus erythematosus (SLE) and to investigate correlation between IL-17 cytokine serums with IL-10 in SLE patients.
METHODS: This study recruited total of 68 SLE patients which included 34 active and 34 inactive patients based 
on MEX-SLEDAI as disease activity tool measurement and subjects were selected using consecutive sampling 
method. Blood samples were taken from subjects and IL-17 and IL-10 were measured using ELISA method. Data 
were analyzed with SPSS 26 software.
RESULTS: Mean IL-17 was 19.67 ± 1.299 pg/ml in active SLE group and 19.78 ± 1.187 pg/ml in inactive group. 
Median of IL-10 in active group was 3.63 pg/ml and in inactive group was 2.52 pg/ml, respectively. No significant 
mean differences were found of IL-17 and IL-10 between active and inactive SLE patients (p > 0.005). We found 
significant positive correlation between IL-17 and IL-10 (p < 0.005; r = 0.529).
CONCLUSION: There were no significant mean differences of IL-17 and IL-10 between active and inactive SLE 
patients. However, we found elevated result of IL-10 in active SLE than inactive. There was positive correlation 
between IL-17 and IL-10.
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Introduction
The occurrence of this disease is a result 
of interactions between genetic, environmental, 
and hormonal, causing immunological disorders. T 
lymphocyte cells (CD4+) play an important role in the 
occurrence of autoimmune diseases. During T cell 
receptor activation, naive CD4 cells can differentiate 
into T-helper (Th)1, Th2, Th17, and T-regulator (T-reg) 
cells based on the production patterns and cytokine 
function of each T-helper cell. In SLE, this imbalance of 
T-helper cell cytokines is also thought to contribute to 
the pathogenesis of SLE [3], [4], [5].
Th17 cells produce cytokines interleukin-17 
(IL-17) which acts as protection in host cells, but 
excessive activity can lead to autoimmune and 
inflammatory conditions. Recent studies also showed 
that homeostatic disorders that occur in autoimmune 
are also caused by disruption of the regulator’s 
function, which are T-reg cells that produce cytokines 
interleukin-10 (IL-10). The Th17/T-reg subset is slowly 
replacing the old paradigm of the relationship between 
B cells and the Th1/Th2 subset in autoimmunity. The 
balance between the activity of immune regulation and 
inflammation of the Th17/T-reg cell subset is absolutely 
necessary in maintaining optimal immunity so that 
interference with this subset will lead to autoimmune 
diseases, especially SLE [6], [7], [8].
Role of the Th17 and T-regulator axis of 
SLE disease activity still shows controversial results. 
Research on IL-17 as a cytokine produced by a subset 
of Th17 and IL-10 as a T-reg cytokine in SLE disease 
activity still shows different results [9], [10].
This study was conducted to compare means 
of IL-17 (Th17 cytokines) and IL-10 (T-regulatory 
cytokines) as pro-inflammatory and anti-inflammatory 
cytokine with disease activity of SLE and to investigate 
correlation between IL-17 cytokine serums with IL-10 in 
SLE patients.
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Methods
This study recruited total of 68 SLE patients 
which included 34 active and 34 inactive patients based 
on MEX-SLEDAI as disease activity tool measurement 
and subjects were selected using consecutive sampling 
method. Patients with infection, severe systemic events, 
and other autoimmune diseases are excluded from the 
study. Research sites are in outpatient Department of 
Allergy and Immunology – Internal Medicine in Cipto 
Mangunkusumo General Hospital in Jakarta. All patients 
have signed the informed consent. This research has 
received an ethical approval from the Ethics Committee 
of Medical Faculty of University of Indonesia.
Blood samples were taken from subjects and 
IL-17 and IL-10 were measured using ELISA method. 
All data are collected and tabulated then statistical 
analysis is computerized using the SPSS version 26. 
A value of p < 0.05 was considered as statistically 
significant.
Results
In this study, from 68 total samples, 100% 
female samples were obtained with a median age of 31 
years with a minimum age of 18 years and a maximum 
age of 65 years. Age group 21–40 years is the most 
commonly found in this study, which is 81.8% and the 
least is the age group 20 years as much as 11.8%. 
Duration of SLE diagnosis in this study was obtained at 
most for >1 year by 82.4%. Disease activity based on 
Table 1: Baseline characteristics
Characteristics n=68
Sex, n (%)
Male 0 (0.0)
Female 68 (100.0)
Age (year old), median (min-max) 31 (18–65)
Age group, n (%)
≤20 year old 8 (11.8)
21–40 year old 32 (81.8)
>40 year old 18 (26.5)
SLE duration, n (%)
≤1 year 12 (17.6)
>1 year 56 (82.4)
Immunosuppressant, n (%)
Without 29 (85.3)
Single drug 23 (67.6)
Two combinations 17 (50)
Three combinations 1 (2.9)
Steroid, n (%)
Without 7 (10.3)
Dose ≤4 mg/hari 37 (54.4)
Dose >4 mg 24 (35.3)
MEX SLEDAI, median (min-max) 1 (0–17)
SLE
Active 34 (50.0)
Inactive 34 (50.0)
IL-17 (pg/ml), Mean (SD) 19.73 (1.24)
IL-10 (pg/ml), median (min-max) 2.96 (0–11)
SLE: Systemic lupus erythematosus, IL: Interleukin, SD: Standard deviation.
the MEX SLEDAI score obtained a median of 1, with a 
minimum score of 0 with a maximum of 17. A total of 34 
SLE patients (50%) were active LES and 50% patients 
were inactive LES. In this study, 85.3% of subjects 
did not use immunosuppressant, followed by 67.6% 
with single immunosuppressant, 50% combination of 
two immunosuppressant, and 2.9% combination of 
three immunosuppressant. The highest steroid dose 
equivalent to 4 mg/day was 54.4% and 10.3% were not 
on steroid therapy. The average IL17 level was 19.73 
(1.24) pg/ml. The median IL-10 level is 2.96 pg/ml with 
a minimum level of 0 pg/ml and a maximum of 11 
pg/ml. Table 1 shows the baseline characteristics of all 
samples.
From this study, a significant positive correlation 
was obtained between IL-17 and IL-10 levels in SLE 
patients with p < 0.001 and r = 0.539, as shown in 
Figure 1.
This study shows that there is no significant 
mean difference between the IL-17 levels of the active 
and inactive SLE groups. IL-10 levels in active SLE were 
higher than inactive SLE but there were no significant 
differences between them (Table 2).
Table 2: Differences between IL-17 and IL-10 mean level with 
SLE disease activity
Variable SLE p
Active Inactive
IL-17, mean (SD) 19.67 (1.299) 19.78 (1.187) 0.711
IL-10, median (min-max) 3.63 (1-11) 2.52 (0-6) 0.099*
SLE: Systemic lupus erythematosus, IL: Interleukin, SD: Standard deviation.
Discussion
In this study, there were 68 female subjects 
with SLE and no men with a median age of 31 years, 
and the most were between the ages of 21 and 40 
years. Predomination of female sex is a characteristic 
of SLE disease as a systemic autoimmune disease, 
in which other studies showed the ratio of women/
men is 9/1–10-15/1, which can reach its peak at 
productive age as shown in this study. The influence of 
hormonal, cytokine, and genetic imbalances is thought 
to play a role in the predominance of female sex in 
this SLE. High estrogen levels and low progesterone 
Figure 1: Correlation between interleukin-17 and interleukin-10 levels 
in systemic lupus erythematosus patients
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in SLE affect the expression of toll-like receptor-17 
mediated IFN-α and chemokine C-X-C ligand 10 in the 
peripheral so that it can cause disease progression 
and SLE disease activity through modulation of the 
IFN-α pathway [11], [12], [13].
The duration of SLE disease in this study 
obtained a median of 4.5 years with SLE disease >1 year 
more than <1 year (82.4% vs. 17.6%). This is consistent 
with research conducted by Kakati et al. which showed 
that SLE disease duration >1 year (71.7%) is more than 
<1 year (28.3%). The Almenara Lupus cohort study 
showed a longer average LES disease of 7.7 years. 
Disease activity in this study was calculated based on 
the MEX-SLEDAI score obtained a median of 1 with 
a minimum value of 0 and a maximum of 17. Based 
on the MEX-SLEDAI criteria, a score of <2 had mild 
activity, in this study categorized as an inactive SLE with 
a total of 34 subjects and scores >2 were categorized 
as active SLE with 34 subjects. In this study, the active 
SLE median obtained 8 with a minimum value of 2 and 
a maximum of 17. The use of MEX-SLEDAI used in this 
study to determine disease activity because based on 
research by Freire et al., MEX-SLEDAI has a higher 
validity than other measuring devices such as British 
Island Lupus Assessment Group and Systemic Lupus 
Activity Measurement and do not require a fee for their 
use [14], [15], [16].
The mean IL-17 level in this study was 19.73 
(1.24) pg/ml. It was seen that IL-17 levels in SLE patients 
were higher than those of Talaat et al., Yao et al., and 
Tsanakti et al. with the mean IL-17 levels were 17.7 
(2.3) pg/ml, 18.23 (8.22) pg/ml, and 9.08 (1.39) pg/ml, 
respectively. Research by Galil et al. showed almost the 
same results as this study, which is 19.47 (10.21) pg/ml 
and studies by Wong et al. and Vincent et al. showed a 
higher mean of IL-17, which are 76.5 (45.7) pg/ml and 
140.6 pg/ml [17], [18], [19], [20], [21], [22].
This study also showed a correlation between 
IL-17 levels and IL-10 serum obtained a significant 
positive correlation with p ≤ 0.05 and r = 0.539. It can 
be seen that the pro-inflammatory activity of IL-17 is 
significantly proportional to the secretion of IL-10 from 
T-reg cells in SLE patients. This is consistent with the 
hypothesis showing that IL-17 and IL-10 have a positive 
correlation in SLE. IL-10 as an anti-inflammatory 
cytokine has the characteristics of cytokines as 
cytokines T-regulator cells especially T regulator type 
1 cells (Tr1) which under normal circumstances can 
inhibit the response of B cells which is an independent 
effect of IL-10. IL-10 itself is not only produced by T-reg 
cells but also produced by other T-helper cells that have 
regulatory functions, besides IL-10 is also a cytokine 
that plays a role in the maturation and differentiation 
factors of B cells, so as to increase survival, proliferation, 
isotype changes, and B cell differentiation to plasma 
cells [23], [24].
In SLE, IL-10 has a proven pathogenic role in 
this study correlating with IL-17 levels which activate the 
formation of autoantibodies (autoreactive B cells) which 
have an impact on increasing disease activity and severity 
of SLE. A study by Facciotti et al. showed that mice with 
SLE secreted IL-10 by T-regulator cells and follicular 
T-helper (Tfh) cell populations which showed that in 
addition to T-regulator cell activity, autoreactive B cells 
also express pathogenic cytokines IL-10 spontaneously 
which induces the formation of autoantibodies in vitro, as 
well as the production of autoantibodies in mice in vivo, 
which until now the pathophysiological mechanism 
is still being investigated further, especially the role of 
follicular T-helper cells in the balance of Th17/Treg cells 
and Th1/Th2 cells. Analysis of IL-10 secretion in other 
T cell subsets has also not been able to identify the 
unique cellular role of these cytokines. The paradoxical 
pathogenic activity of IL-10 in SLE is still interesting 
to study considering that the capacity of IL-10 has not 
yet been identified that independently stimulates the 
production of autoantibodies, so it is suspected that 
there is involvement of other T-set subset pathways 
that contribute to this stimulation. A study by Su et al. 
demonstrated the involvement of microRNA (miRNAs) 
in the stimulation of IL-10 in SLE. The dysregulation 
of miR-199-3p expression increases IL-10 production 
which targets Poly (ADP-ribose) polymerase-1 which 
is a serological marker found in SLE patients and is 
associated with inflammatory factors and cytokines, 
but the role of miRNA in the pathogenesis of SLE is still 
being evaluated, especially its impact on the clinical and 
activity of SLE disease [23], [24], [25], [26].
This study showed that there is no difference in 
the mean IL-17 serum levels of active and inactive SLE 
patients. This result is different from study conducted by 
Talaat et al. and Galil et al. which showed a significant 
mean difference between the IL-17 levels of active and 
inactive SLE patients, while the study of Zhao et al. 
which involved 41 active and 16 inactive SLE patients 
showed no significant mean difference between the 
two groups. The study conducted by Yao et al. showed 
that there was a mean difference between active and 
inactive SLE with p = 0.041 although it was not related 
to disease activity score (SLEDAI). Yao et al. also 
classifying between active SLE with neuropsychiatric 
lupus involvement (NPSLE) and without NPSLE found 
no significant difference (18.23 and 18.77 pg/ml). The 
comparison between IL-17 levels in active and inactive 
SLE patients still show different results in each study. 
Previous study has involved healthy controls as a 
comparison, in which it showed that active SLE patients 
secrete IL-17 influenced by the induction of adhesion 
molecules such as cell surface cadherin, integrin, 
selectins, ICAM-1, and VCAM, which when compared 
with controls healthy will show results of higher 
IL-17 levels, thus allowing the role of lymphocytes 
and antigen-presenting cells in the development of 
autoimmune responses, but studies in the inactive SLE 
group have not been conducted yet. In addition, defects 
in the development and activity of regulator T-CD4 cells 
both in terms of quantity and quality also affect the ability 
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of cells to suppress the proliferation and production of 
IL-17 proinflammatory cytokines in immune cell effector 
in SLE patients, so there is a possibility that IL-17 can 
contribute to the ability of T-regulator cell inhibition due 
to reciprocal control in the formation and supervision 
of Th17 cells and T-regulator cells [17], [18], [19], [27].
The results of this study also showed no mean 
difference between IL-10 active and inactive SLE 
patients, but a median serum IL-10 value was higher 
in the active group than inactive. In addition, IL-10 
levels also showed higher results than inactive SLE. 
Serum IL-10 was also found to be higher in the study 
of Koenig et al. that conducted in the SLE group with 
active nephritis compared to inactive and control SLE, 
although the sample used was limited to 12 subjects. A 
study by Godsell et al. involving 129 active SLE patients 
who underwent IL-10 examination at the first visit and 
continued 2 years later showed that serum IL-10 could 
be a predictive factor for the possibility of relapse in SLE 
patients. In the study, it was mentioned that patients 
with the highest quartile at the time of initial diagnosis of 
SLE had a 3.6-fold potential to experience active SLE 
in subsequent controls, and this result also correlated 
with SLE inflammatory markers such as erythrocyte 
sedimentation rate, anti-dsDNA, levels C3 and C4, and 
significant correlations were also obtained at the next 
SLE patient visit, so from this study it was seen that 
serum IL-10 levels might be a marker of disease activity 
in SLE patients [28], [29], [30].
Conclusion
There were no significant mean differences 
of IL-17 and IL-10 between active and inactive SLE 
patients on this study. However, we found elevated result 
of IL-10 in active SLE than inactive which described 
the activity of anti-inflammatory cytokines produced by 
T-regulatory cells were higher in active SLE. There was 
positive correlation between IL-17 and IL-10.
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